Am­gen takes a swing at re­gen­er­a­tive im­munol­o­gy with $721M ac­qui­si­tion of Rodeo Ther­a­peu­tics

With block­buster im­munol­o­gy meds En­brel and Ote­zla al­ready in the fold, Am­gen has most­ly stood pat on in­fus­ing new blood in­to its lega­cy pipeline. But that suc­cess won’t last for­ev­er, and Am­gen is tak­ing a far-look­ing bet on a pri­vate biotech forg­ing a new path­way to treat im­mune sys­tem dis­eases.

Am­gen will pay $55 mil­lion up­front and a dev­il­ish $666 mil­lion in fu­ture mile­stones to ac­quire Seat­tle-based Rodeo Ther­a­peu­tics and its small-mol­e­cule ther­a­pies tar­get­ing the 15-prostaglandin de­hy­dro­ge­nase (15-PGDH) en­zyme po­ten­tial­ly im­pli­cat­ed in a range of in­di­ca­tions, the com­pa­nies said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER